Project Grant R41TR003571

COMPUTATIONAL PREDICTION OF GUT MICROBIOME-MEDIATED DRUG METABOLISM - PROJECT SUMMARY / ABSTRACT NOTWITHSTANDING PRE-CLINICAL EXPERIMENTS AND CLINICAL TRIALS PERFORMED TO IDENTIFY EFFICACY, SIDE EFFECTS, AND ADVERSE DRUG REACTIONS (ADRS), ONLY 25-60% OF PATIENTS RESPOND FAVORABLY TO PRESCRIBED DRUGS, LEADING TO A COST OF $30-$130 BILLION IN THE US ANNUALLY. ADRS ARE PARTIALLY ATTRIBUTED TO THE GUT MICROBIOME, I.E. THE COMPLEX AND DYNAMIC COMMUNITY OF MICROORGANISMS RESIDING IN GASTROINTESTINAL TRACT. THE GUT MICROBIOME INTERACTS WITH DIFFERENT TYPES OF XENOBIOTICS INCLUDING DRUGS, RESULTING IN BIOTRANSFORMATION OF THERAPEUTICS INTO METABOLITES WITH ALTERED DISPOSITION, EFFICACY, AND TOXICITY. GUT MICROBIOME-MEDIATED DRUG METABOLISM LEADS TO NON-EFFECTIVE TREATMENTS AS WELL AS TERATOGENIC, TOXIC, AND LETHAL EFFECTS THAT IN SOME CASES WERE NOT RECOGNIZED UNTIL THE DRUG WAS ON THE MARKET. AS A RESULT, LEADING PHARMACEUTICAL RESEARCHERS HAVE BEGUN TO RECOGNIZE THAT THE ROLE OF GUT MICROBIOME IN DRUG METABOLISM SHOULD BE ACCOUNTED FOR IN ATTEMPTS TO IMPROVE TREATMENT EFFECTIVENESS. HOWEVER, DESPITE EXTENSIVE PROGRESS IN GUT MICROBIOME RESEARCH, THERE IS CURRENTLY NO RELIABLE, COST-EFFECTIVE APPROACH TO INTEGRATE GUT-MEDIATED DRUG METABOLISM IN DRUG DEVELOPMENT PIPELINES. THIS PHASE I PROPOSAL AIMS TO ADDRESS THIS CHALLENGE BY DEVELOPING A NEW COMPUTATIONAL PLATFORM WITH THE ABILITY TO PREDICT MICROBIAL METABOLISM OF THERAPEUTIC DRUGS AND TO LEVERAGE THAT INFORMATION TO ENHANCE DRUG DESIGN AND DEVELOPMENT. WE WILL EMPLOY A RANGE OF STATE-OF-THE-ART COMPUTATIONAL BIOLOGY TECHNIQUES TO RELIABLY SCREEN FOR MICROORGANISMS THAT MAY METABOLIZE THE TARGET DRUGS. THE NOVELTY OF THIS PROJECT LIES IN THE ABILITY TO SCREEN DRUG-METABOLIZING ENZYMES/MICROORGANISMS USING MULTIPLE METRICS AND METHODS TO INCREASE THE RELIABILITY OF PREDICTIONS TO ACHIEVE THE ACCURACY NECESSARY FOR CLINICAL AND COMMERCIAL USE. THIS MULTI- METHOD PLATFORM WILL BE BUILT, INTEGRATED, AND VALIDATED IN AN ITERATIVE FASHION USING TARGETED IN VITRO EXPERIMENTS ON TWO CANDIDATE DRUGS, I.E. THE ANTI-ARRHYTHMIC DRUG AMIODARONE AND THE ANTI-VIRAL DRUG FAMCICLOVIR. THIS PROJECT IS DESIGNED TO BOTH ADVANCE OUR CURRENT UNDERSTANDING OF MICROBIOME FUNCTION IN THE CONTEXT OF DRUG-GUT INTERACTIONS AS WELL AS INFORM STRATEGIES TO HELP ENHANCE PUBLIC HEALTH AND ECONOMIC GROWTH. THE VALUE PROPOSITION OF THIS PROJECT INCLUDES LEVERAGING PUBLICLY AVAILABLE BIOINFORMATICS DATABASES AS WELL AS ADVANCES IN COMPUTATIONAL BIOLOGY TECHNIQUES TO DEVELOP A MORE PRECISE, RELIABLE, AND INEXPENSIVE TOOL FOR GUT MICROBIOME-MEDIATED METABOLISM OF THERAPEUTIC DRUGS. THIS IN-SILICO PLATFORM COULD BE EMPLOYED FOR BOTH CURRENT DRUGS AS WELL AS DRUGS UNDER DEVELOPMENT. FOR CURRENT DRUGS, THIS PLATFORM CAN HELP INCREASE THE SAFETY OF DRUGS BY PREDICTING THE MECHANISMS OF EFFICACY AND TOXICITY AS THEY MAY DIFFER FROM INDIVIDUAL-TO- INDIVIDUAL. FOR NEW DRUGS, THE PLATFORM WOULD REDUCE THE COST AND TIMEFRAME OF DRUG DEVELOPMENT, WHILE INCREASING THE EFFECTIVENESS OF THE THERAPEUTICS THEMSELVES.